NCT00551421View on ClinicalTrials.gov

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

June 30, 2012

Conditions
Adenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
Interventions
BIOLOGICAL

pertuzumab

Given IV

BIOLOGICAL

cetuximab

Given IV

DRUG

irinotecan hydrochloride

Given IV

OTHER

immunohistochemistry staining method

Correlative study

OTHER

fluorescence in situ hybridization

Correlative study

OTHER

gene expression analysis

Correlative study

OTHER

mutation analysis

Correlative study

OTHER

polymerase chain reaction

Correlative study

OTHER

laboratory biomarker analysis

Correlative study

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00551421 - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter